Janssen Collaborates with Vor to Develop Engineered Hematopoietic Stem Cell Transplants with Bi-Specific Antibody Therapy to Treat AML
Shots:
- The collaboration will evaluate the combination of Vor’s eHSC transplant platform with Janssen’s bi-specific Abs for the treatment of AML
- The agreement stated that each company retains all rights and ownership to their respective programs and platforms
- The combination will utilize each technology’s strengths for protecting patients against off-target effects of immunotherapies
Ref: Globe Newswire | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
